journal article·2024-09Open access

The TDP‐43/TP63 Positive Feedback Circuit Promotes Esophageal Squamous Cell Carcinoma Progression

Wenwen Li, Yanting Yang, Linying Huang, Xinyuan Yu, Teng Wang, Nasha Zhang, Ming Yang

Advanced Science· Volume 11· Issue 35

Abstract

Abstract Esophageal squamous cell carcinoma (ESCC) is one of the most prevalent malignancies with a 5‐year survival rate of only 15% in patients with advanced diseases. Tumor protein 63 (TP63), a master transcription factor (TF) in ESCC, cooperates with other TFs to regulate enhancers and/or promoters of target oncogenes, which in turn promotes tumorigenesis. TAR‐DNA‐binding protein‐43 (TDP‐43) is an RNA/DNA binding protein with elevated expression in several neoplasms. However, it remains unclear how TDP‐43 contributes to ESCC progression. In this study, TDP‐43 is identified as a novel oncogene with markedly upregulated expression in ESCC tissues through profiling expression levels of one hundred and fifty canonical RNA binding protein (RBP) genes in multiple ESCC patient cohorts. Importantly, TDP‐43 boosted TP63 expression via post‐transcriptionally stabilizing TP63 mRNAs as a RBP and promoting TP63 transcription as a TF binding to the TP63 promoter in ESCC cells. In contrast, the master TF TP63 also bound to the TDP‐43 promoter, accelerated TDP‐43 transcription, and caused a noticeable increase in TDP‐43 expression in ESCC cells. The findings highlight TDP‐43 as a viable therapeutic target for ESCC and uncover a hitherto unrecognized TDP‐43/TP63 circuit in cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA modifications and cancer · RNA Research and Splicing · Cancer-related molecular mechanisms research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shandong Provincial Key Laboratory of Radiation Oncology Cancer Research Center Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences Jinan Shandong 250117 China

School of Life Sciences Shandong First Medical University and Shandong Academy of Medical Sciences Taian Shandong 271021 China

Shandong University Cancer Center Jinan Shandong 250117 China

Department of Radiation Oncology Shandong Cancer Hospital and Institute Jinan Shandong 250117 China

Jiangsu Key Lab of Cancer Biomarkers Prevention and Treatment Collaborative Innovation Center for Cancer Personalized Medicine Nanjing Medical University Nanjing Jiangsu 211166 China

Funding

National Natural Science Foundation of China · Natural Science Foundation of Shandong Province · Major Scientific and Technological Innovation Project of Shandong Province

References (52)

Show source-provided references
1. 10.1016/j.gtc.2022.06.00510.1016/j.gtc.2022.06.005 ↗
2. 10.1053/j.gastro.2022.05.05410.1053/j.gastro.2022.05.054 ↗
3. 10.1016/S1470-2045(14)70024-510.1016/S1470-2045(14)70024-5 ↗
4. 10.1016/S1470-2045(20)30110-810.1016/S1470-2045(20)30110-8 ↗
5. 10.1056/NEJMoa203212510.1056/NEJMoa2032125 ↗
6. 10.1016/S0140-6736(17)33326-310.1016/S0140-6736(17)33326-3 ↗
7. 10.1186/s13045-020-00927-w10.1186/s13045-020-00927-w ↗
8. 10.1016/j.trecan.2017.05.00310.1016/j.trecan.2017.05.003 ↗
9. 10.1038/emboj.2009.32410.1038/emboj.2009.324 ↗
10. 10.1073/pnas.111242710910.1073/pnas.1112427109 ↗
11. 10.1016/j.mcn.2019.10339610.1016/j.mcn.2019.103396 ↗
12. 10.15252/embj.202110844310.15252/embj.2021108443 ↗
13. 10.1038/s41419-022-04867-w10.1038/s41419-022-04867-w ↗
14. 10.1007/s13238-017-0480-910.1007/s13238-017-0480-9 ↗
15. 10.1016/j.molcel.2019.03.04110.1016/j.molcel.2019.03.041 ↗
16. 10.1073/pnas.080054610510.1073/pnas.0800546105 ↗
17. 10.1016/j.cell.2011.01.01310.1016/j.cell.2011.01.013 ↗
18. 10.1038/ncb304010.1038/ncb3040 ↗
19. 10.1242/jcs.22801510.1242/jcs.228015 ↗
20. 10.4161/cc.6.3.379310.4161/cc.6.3.3793 ↗
21. 10.1038/1953910.1038/19539 ↗
22. 10.1093/nar/gkab67910.1093/nar/gkab679 ↗
23. 10.1053/j.gastro.2020.06.05010.1053/j.gastro.2020.06.050 ↗
24. 10.1053/j.gastro.2018.02.01810.1053/j.gastro.2018.02.018 ↗
25. 10.1158/0008-5472.CAN-22-192310.1158/0008-5472.CAN-22-1923 ↗
26. 10.1016/j.canlet.2023.21643610.1016/j.canlet.2023.216436 ↗
27. 10.1038/s41388-023-02855-810.1038/s41388-023-02855-8 ↗
28. 10.15252/embr.20215270710.15252/embr.202152707 ↗
29. 10.7150/thno.4824710.7150/thno.48247 ↗
30. 10.1002/ctm2.110710.1002/ctm2.1107 ↗
31. 10.1016/j.cell.2021.07.01810.1016/j.cell.2021.07.018 ↗
32. 10.1016/j.addr.2022.11417910.1016/j.addr.2022.114179 ↗
33. 10.1016/j.semcancer.2022.03.01810.1016/j.semcancer.2022.03.018 ↗
34. 10.1016/j.cell.2019.06.00110.1016/j.cell.2019.06.001 ↗
35. 10.1186/gb-2014-15-1-r1410.1186/gb-2014-15-1-r14 ↗
36. 10.1016/j.celrep.2018.01.08810.1016/j.celrep.2018.01.088 ↗
37. 10.1080/15476286.2019.167365710.1080/15476286.2019.1673657 ↗
38. 10.1038/s41392-021-00847-210.1038/s41392-021-00847-2 ↗
39. 10.1016/j.canlet.2016.02.02110.1016/j.canlet.2016.02.021 ↗
40. Feixia Guo H. W. · Cancer Res. · 2020 · 10 · 3285
41. Pierre P. M. T. · Cancer Res. · 2003 · 63 · 7113
42. The Cancer Genome Atlas Research Network Nat.2017 541 169.10.1038/nature20805 ↗
43. Li M. Y. · J. Clin. Invest. · 2020 · 130 · 4301
44. 10.1158/0008-5472.CAN-18-174910.1158/0008-5472.CAN-18-1749 ↗
45. 10.1080/15384047.2023.224620510.1080/15384047.2023.2246205 ↗
46. 10.1073/pnas.143210410010.1073/pnas.1432104100 ↗
47. 10.1038/sj.emboj.760158810.1038/sj.emboj.7601588 ↗
48. 10.1016/j.cell.2019.04.01310.1016/j.cell.2019.04.013 ↗
49. 10.1186/s13046-022-02339-910.1186/s13046-022-02339-9 ↗
50. 10.1073/pnas.030645310110.1073/pnas.0306453101 ↗
51. 10.1016/j.bcp.2010.06.03310.1016/j.bcp.2010.06.033 ↗
52. 10.1038/s42003-020-0933-110.1038/s42003-020-0933-1 ↗